Phosphatidylglycerol Nanovesicles for Blocking M2 Macrophage Polarization

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Cancer cells establish an immunosuppressive tumor microenvironment through M2 macrophage polarization, which promotes tumor growth and survival, and existing therapies fail to effectively inhibit this mechanism.

Innovation Solution

Administering phosphatidylglycerol nanovesicles (NVs) to sequester cancer-secreted heat shock protein 70 (Hsp70), thereby inhibiting M2 macrophage polarization and reducing the immunosuppressive nature of the tumor microenvironment.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If cancer cells secrete Hsp70 to induce M2 macrophage polarization, then tumor growth and survival are promoted, but the immunosuppressive nature of the tumor microenvironment is enhanced

Engineering Contradiction:

Improvetumor growthVSAvoidimmunosuppressive nature

Core Design Contradiction:

ProductivityVSObject-generated harmful factors

Solution Approach 1:

The patent extracts and removes Hsp70 from the tumor microenvironment using phosphatidylglycerol nanovesicles that specifically bind and sequester this protein, preventing it from inducing M2 macrophage polarization and thereby eliminating its harmful immunosuppressive effects

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The phosphatidylglycerol nanovesicles act as intermediary agents that intercept Hsp70 before it can interact with macrophages, serving as a mediator to block the harmful signaling pathway while allowing normal immune function to proceed

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If M2 macrophages are recruited to the tumor site, then tumor survival is sustained through immune suppression, but the ability of the host immune system to attack the tumor is reduced

Engineering Contradiction:

Improvetumor survivalVSAvoidimmune attack capability

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies preliminary anti-action by pre-positioning phosphatidylglycerol nanovesicles in the tumor microenvironment that are ready to bind and neutralize Hsp70 before it can activate M2 macrophage polarization, thereby preventing the harmful immune suppression from occurring in the first place

Inventive Principle:

Principle #9Preliminary anti-action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The sequestration of Hsp70 by phosphatidylglycerol NVs reduces tumor volume and shifts macrophage polarization towards the M1 phenotype, effectively inhibiting tumor growth.

Implementation Method 1

sequestration of Hsp70 by immunotherapeutic phospholipid nanovesicles reduces tumor growth

Methodology Applied

Scientific EffectSequestration: Absorption (physical)

Data Source

PatentUS20260069620A1Immunotherapeutic phospholipids for cancer treatment

Publication Date: 2026.03.12 UNIVERSITY OF CINCINNATI

AI summary

A method of treating cancer in a subject is provided, the method including administering to the subject a therapeutic amount of a composition including phosphatidylglycerol nanovesicles (NVs). A method of inhibiting M2 macrophage polarization in a tumor microenvironment by administering phosphatidylglycerol NVs is also provided, together with pharmaceutical compositions including phosphatidylglycerol NVs.